101 Views | 67 Downloads
Philip J. Santangelo, Philip.j.santangeloemory.edu
J.P.B., S.B., and P.J.S. conceived the study and designed the experiments. J.P.B., S.B., H.E.P., R.A.H., and J.A.W. performed the experiments. H.E.P. produced the mRNA. J.P.B. and J.A.W. formulated LNPs. N.I. and C.A.G. conceived of, created, and validated the VPH-dCas9-SS18 construct. J.P.B., S.B., and P.J.S. wrote the manuscript. J.P.B., S.B., N.I., C.Z., J.A.W., P.J.S., and C.A.G. edited the manuscript. J.P.B., S.B., and N.I. contributed equally to this work.
The authors declare the following competing financial interest(s): All authors declare no competing interests related to this work. NI and CAG are inventors on patent applications regarding CRISPR technologies and targeted gene activation. CAG is an advisor to Tune Therapeutics, Sarepta Therapeutics, and Levo Therapeutics, and a co-founder of Tune Therapeutics and Locus Biosciences.
This study was supported by the Defense Advanced Research Projects Agency, Grant No. HR00111920008, National Institutes of Health Grant No. U01AI146356, National Science Foundation Grant No. EFMA-1830957, and an Allen Distinguished Investigator Award to C.A.G.
© 2022 The Authors. Published by American Chemical Society